CLLS Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat Biodexa Pharmaceuticals PLC's return on equity of --.

Cellectis SA has a consensus price target of --, signalling upside risk potential of 327.35%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that Cellectis SA has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Cellectis SA is more attractive than Biodexa Pharmaceuticals PLC.

Cellectis SA has a beta of 3.093, which suggesting that the stock is 209.338% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $16.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.81x versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat DBV Technologies SA's return on equity of --.

Cellectis SA has a consensus price target of --, signalling upside risk potential of 327.35%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 624.09%. Given that DBV Technologies SA has higher upside potential than Cellectis SA, analysts believe DBV Technologies SA is more attractive than Cellectis SA.

Cellectis SA has a beta of 3.093, which suggesting that the stock is 209.338% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.81x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -142.32% compared to Cellectis SA's net margin of -48.85%. Cellectis SA's return on equity of -79.78% beat Edap TMS SA's return on equity of -42.5%.

Cellectis SA has a consensus price target of --, signalling upside risk potential of 327.35%. On the other hand Edap TMS SA has an analysts' consensus of -- which suggests that it could grow by 387.04%. Given that Edap TMS SA has higher upside potential than Cellectis SA, analysts believe Edap TMS SA is more attractive than Cellectis SA.

Cellectis SA has a beta of 3.093, which suggesting that the stock is 209.338% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.329, suggesting its less volatile than the S&P 500 by 67.134%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $16.2M, which are larger than Edap TMS SA quarterly revenues of $14.4M. Cellectis SA's net income of -$23.1M is lower than Edap TMS SA's net income of -$7M. Notably, Cellectis SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.81x versus 1.18x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat Genfit SA's return on equity of --.

Cellectis SA has a consensus price target of --, signalling upside risk potential of 327.35%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 180.13%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

Cellectis SA has a beta of 3.093, which suggesting that the stock is 209.338% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $16.2M, which are larger than Genfit SA quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than Genfit SA's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.81x versus 2.66x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.